First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR
Gesamtkosten:
CHF287,823.40
Beteiligte
(Contact person)- PSI - Paul Scherrer Institut
- Ymmunobio AG
- www.uid.admin.ch/Detail.aspx?uid_id=CHE433951246
- PSI - Paul Scherrer Institut
Abstract
Key words
Abstract